Helix BioPharma Reports Fiscal 2026 Loss of C$0.04 Per Share
Photo: TokenPost
Helix BioPharma Corp. reported a fiscal 2026 loss of C$0.04 per share for the year ended July 31, 2026, a 55.6% narrowing from the C$0.09 loss per share a year earlier. The company had C$804,000 in cash reserves on July 31, compared with C$65,000 a year earlier. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
